サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1791747

非アルコール性脂肪性肝炎臨床試験の世界市場

Non-alcoholic Steatohepatitis Clinical Trials

出版日
ページ情報
英文 144 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.53円
非アルコール性脂肪性肝炎臨床試験の世界市場
出版日: 2025年08月15日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 144 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

非アルコール性脂肪性肝炎臨床試験の世界市場は2030年までに43億米ドルに達する見込み

2024年に32億米ドルと推定される非アルコール性脂肪性肝炎臨床試験の世界市場は、2024年から2030年にかけてCAGR 5.5%で成長し、2030年には43億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるフェーズiは、CAGR6.8%を記録し、分析期間終了時には20億米ドルに達すると予測されます。フェーズIIセグメントの成長率は、分析期間中CAGR 3.9％と推定されます。

米国市場は8億2,880万米ドルと推定、中国はCAGR 5.3％で成長予測

米国の非アルコール性脂肪性肝炎臨床試験市場は、2024年に8億2,880万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに6億9,780万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは5.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ5.3％と4.6％と予測されています。欧州では、ドイツがCAGR 4.3%で成長すると予測されています。

世界の非アルコール性脂肪性肝炎（NASH）臨床試験市場- 主要動向と促進要因のまとめ

なぜNASH臨床試験の需要が急増しているのか？

非アルコール性脂肪性肝炎（NASH）の世界の負担増は、この複雑な肝疾患に対する効果的な治療介入の開発を目的とした臨床試験の需要に拍車をかけています。他の代謝性疾患とは異なり、NASHには現在FDAが承認した治療法がないため、肝線維化と疾患の進行を予防できる潜在的な薬剤候補を特定するための臨床研究が不可欠となっています。製薬会社やバイオテクノロジー企業は、NASHの薬剤開発に多額の投資を行っており、炎症、線維化、脂質代謝など異なる疾患経路を標的とする複数の化合物が第II相および第III相臨床試験段階にあります。研究者が遺伝的、ライフスタイル的、代謝的因子が疾患の進行や治療効果にどのように影響するかを理解しようとするため、試験における多様な患者集団の必要性も高まっています。さらに、規制当局は有望なNASH治療薬に対して迅速臨床試験指定や優先審査を行い、大規模臨床試験への投資を促しています。ヘルスケア業界が代謝性肝疾患の研究を優先させる中、NASH臨床試験市場は大きく拡大し、次世代の肝臓治療薬への道を開いています。

NASH臨床試験の進展に影響を与える課題とは？

NASH研究への投資が増加しているにもかかわらず、臨床試験は医薬品開発のタイムラインと成功率に影響するいくつかのハードルに直面しています。最も重大な課題の一つは患者のリクルートとリテンションです。NASHは初期段階では無症状であることが多く、適格な試験参加者を特定することが困難です。治療効果を評価する主要評価項目が肝生検に依存していることも、患者の侵襲的処置への参加意欲を制限するため、課題となっています。さらに、NASHの病態生理は不均一であるため、様々な患者サブグループで異なるメカニズムが病勢進行に寄与しており、薬剤開発が複雑になっています。規制当局の不確実性や世界市場によって異なる承認基準は、試験の進行をさらに遅らせ、企業は複雑なコンプライアンス体制を乗りこなす必要があります。さらに、後期臨床試験におけるNASH治療薬候補の高い失敗率は、潜在的な治療法の商業的実行可能性に対する懸念を引き起こしています。これらの課題に対処するには、試験デザインの改善、より優れた非侵襲的バイオマーカー、創薬活動を加速させるための利害関係者間の協力体制の強化が必要です。

イノベーションと新たな治療法はNASH臨床試験の将来をどのように形成しているか？

薬剤開発と臨床試験手法の進歩はNASH研究に変革をもたらし、治療法のブレークスルーを成功させる可能性を高めています。プレシジョン・メディシン・アプローチにより、遺伝子および代謝プロファイルに基づく患者の層別化が可能になり、研究者は特定の疾患サブタイプに合わせた治療を行えるようになっています。AIを駆使した臨床試験管理システムの利用は、患者の募集を改善し、脱落率を減らし、試験効率を最適化しています。マルチパラメトリックMRIや一過性エラストグラフィなどの非侵襲的イメージング技術は、生検を必要とせずに肝臓の健康状態を評価するために臨床試験に組み込まれ、患者のコンプライアンスを向上させています。さらに、複数の疾患経路を同時に標的とする併用療法は、NASHの複雑な進行に対処する上で有望です。FXRアゴニスト、PPARアゴニスト、抗線維化剤を含む新規薬剤クラス別が登場したことで、治療の展望がさらに多様化し、治療承認の可能性が高まっています。このような技術革新が進化を続ける中、NASH臨床試験市場が再構築され、効果的で利用しやすい肝疾患治療薬の開発が加速しています。

NASH臨床試験市場の成長の原動力は？

NASH臨床試験市場の成長は、FDA承認の治療に対する緊急のニーズ、代謝性肝疾患の有病率の増加、非侵襲的診断ツールの進歩など、いくつかの要因によってもたらされます。代謝性疾患治療薬への製薬投資の拡大は、複数のバイオファーマ企業が最初に承認されたNASH治療薬の市場投入を目指して競争していることから、試験活動に拍車をかけています。デジタルヘルスプラットフォームやAI主導の患者モニタリングソリューションの採用拡大により、臨床試験の効率化、コスト削減、データ収集精度の向上が進んでいます。さらに、希少疾病用医薬品の指定、迅速承認、画期的治療の指定などの規制上のインセンティブが、医薬品開発者にハイリスク・ハイリターンのNASH研究への投資を促しています。試験デザインにおけるリアルワールドエビデンス（RWE）の役割の増大は、長期的な治療結果に関する貴重な洞察を提供し、市場力学をさらに形成しています。臨床研究が進化を続ける中、NASH臨床試験市場は急速な成長を遂げ、この広範な肝疾患に対する効果的でスケーラブルな治療への進展を促進すると予想されます。

セグメント

フェーズ（第I相、第II相、第III相、第IV相）;試験（介入試験、観察試験、拡大アクセス試験）

調査対象企業の例

  • 89bio, Inc.
  • Akero Therapeutics, Inc.
  • Alimentiv Inc.
  • Allergan plc
  • Boehringer Ingelheim
  • Cadila Healthcare Limited
  • FOMAT Medical Research
  • Gilead Sciences, Inc.
  • ICON plc
  • Intercept Pharmaceuticals, Inc.
  • Laboratory Corporation of America Holdings（LabCorp）
  • Madrigal Pharmaceuticals, Inc.
  • NGM Biopharmaceuticals, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Poxel SA
  • ProSciento, Inc.
  • Viking Therapeutics, Inc.
  • Zealand Pharma A/S

AI統合

検証された専門家のコンテンツとAIツールにより、市場情報と競合情報を変革します。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP32361

Global Non-alcoholic Steatohepatitis Clinical Trials Market to Reach US$4.3 Billion by 2030

The global market for Non-alcoholic Steatohepatitis Clinical Trials estimated at US$3.2 Billion in the year 2024, is expected to reach US$4.3 Billion by 2030, growing at a CAGR of 5.5% over the analysis period 2024-2030. Phase I, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the Phase II segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$828.8 Million While China is Forecast to Grow at 5.3% CAGR

The Non-alcoholic Steatohepatitis Clinical Trials market in the U.S. is estimated at US$828.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$697.8 Million by the year 2030 trailing a CAGR of 5.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.3% and 4.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Global Non-Alcoholic Steatohepatitis (NASH) Clinical Trials Market - Key Trends & Drivers Summarized

Why Is the Demand for NASH Clinical Trials Growing Rapidly?

The rising global burden of non-alcoholic steatohepatitis (NASH) has fueled the demand for clinical trials aimed at developing effective therapeutic interventions for this complex liver disease. Unlike other metabolic disorders, NASH currently has no FDA-approved treatments, making clinical research essential for identifying potential drug candidates that can prevent liver fibrosis and disease progression. Pharmaceutical and biotechnology companies are investing heavily in NASH drug development, with multiple compounds in Phase II and III clinical trials targeting different disease pathways, including inflammation, fibrosis, and lipid metabolism. The need for diverse patient populations in trials is also increasing, as researchers seek to understand how genetic, lifestyle, and metabolic factors influence disease progression and treatment response. Additionally, regulatory agencies are providing fast-track designations and priority reviews for promising NASH therapies, encouraging investment in large-scale clinical trials. As the healthcare industry prioritizes metabolic liver disease research, the NASH clinical trials market is experiencing significant expansion, paving the way for the next generation of liver therapeutics.

What Challenges Are Impacting the Progress of NASH Clinical Trials?

Despite increased investment in NASH research, clinical trials face several hurdles that affect drug development timelines and success rates. One of the most significant challenges is patient recruitment and retention, as NASH is often asymptomatic in its early stages, leading to difficulties in identifying eligible trial participants. The reliance on liver biopsy as a primary endpoint for assessing treatment efficacy also poses a challenge, as it limits patient willingness to participate in invasive procedures. Additionally, the heterogeneity of NASH pathophysiology complicates drug development, as different mechanisms contribute to disease progression in various patient subgroups. Regulatory uncertainties and varying approval criteria across global markets further slow down trial progression, requiring companies to navigate complex compliance frameworks. Moreover, the high failure rate of NASH drug candidates in late-stage trials has raised concerns about the commercial viability of potential treatments. Addressing these challenges will require improved trial designs, better non-invasive biomarkers, and greater collaboration between stakeholders to accelerate drug discovery efforts.

How Are Innovations and Emerging Therapies Shaping the Future of NASH Clinical Trials?

Advancements in drug development and clinical trial methodologies are transforming NASH research, increasing the likelihood of successful therapeutic breakthroughs. Precision medicine approaches are enabling patient stratification based on genetic and metabolic profiles, allowing researchers to tailor treatments to specific disease subtypes. The use of AI-powered clinical trial management systems is improving patient recruitment, reducing dropout rates, and optimizing trial efficiency. Non-invasive imaging techniques, such as multiparametric MRI and transient elastography, are being integrated into trials to assess liver health without requiring biopsies, improving patient compliance. Additionally, combination therapies targeting multiple disease pathways simultaneously are showing promise in addressing the complexity of NASH progression. The emergence of novel drug classes, including FXR agonists, PPAR agonists, and anti-fibrotic agents, is further diversifying the therapeutic landscape, increasing the chances of successful treatment approvals. As these innovations continue to evolve, they are reshaping the NASH clinical trials market, accelerating the development of effective and accessible liver disease treatments.

What Is Driving the Growth of the NASH Clinical Trials Market?

The growth in the NASH clinical trials market is driven by several factors, including the urgent need for FDA-approved treatments, increasing prevalence of metabolic liver diseases, and advancements in non-invasive diagnostic tools. The expansion of pharmaceutical investments in metabolic disorder therapeutics is fueling trial activity, with multiple biopharma companies competing to bring the first approved NASH drug to market. The growing adoption of digital health platforms and AI-driven patient monitoring solutions is improving trial efficiency, reducing costs, and enhancing data collection accuracy. Additionally, regulatory incentives such as orphan drug designations, fast-track approvals, and breakthrough therapy designations are encouraging drug developers to invest in high-risk, high-reward NASH research. The increasing role of real-world evidence (RWE) in trial designs is further shaping market dynamics, providing valuable insights into long-term treatment outcomes. As clinical research continues to evolve, the NASH clinical trials market is expected to witness rapid growth, driving progress toward effective and scalable treatments for this widespread liver disease.

SCOPE OF STUDY:

The report analyzes the Non-alcoholic Steatohepatitis Clinical Trials market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Phase (Phase I, Phase II, Phase III, Phase IV); Study (Interventional Studies, Observational Studies, Expanded Access Studies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • 89bio, Inc.
  • Akero Therapeutics, Inc.
  • Alimentiv Inc.
  • Allergan plc
  • Boehringer Ingelheim
  • Cadila Healthcare Limited
  • FOMAT Medical Research
  • Gilead Sciences, Inc.
  • ICON plc
  • Intercept Pharmaceuticals, Inc.
  • Laboratory Corporation of America Holdings (LabCorp)
  • Madrigal Pharmaceuticals, Inc.
  • NGM Biopharmaceuticals, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Poxel SA
  • ProSciento, Inc.
  • Viking Therapeutics, Inc.
  • Zealand Pharma A/S

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Non-alcoholic Steatohepatitis Clinical Trials - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Obesity and Type 2 Diabetes Propels Growth in NASH Clinical Trials
    • Increased Awareness and Diagnosis Rates Expands Addressable Market Opportunity for NASH Therapeutics
    • Shift Toward Non-Invasive Diagnostic Tools Drives Adoption of Innovative Biomarkers in Clinical Trials
    • Regulatory Push for Accelerated Approval Pathways Strengthens Business Case for NASH Drug Development
    • Advances in Fibrosis Scoring and Imaging Technologies Accelerate Demand for Precision Trial Design
    • Growing Investment from Big Pharma Spurs Growth in Late-Stage Clinical Trials
    • Integration of AI and Predictive Analytics in Trial Design Enhances Trial Efficiency and Outcomes
    • Surging Demand for Personalized Medicine Approaches Drives Growth in Stratified NASH Trial Models
    • Rising Cost and Complexity of Clinical Trials Throws the Spotlight on Outsourcing and CRO Partnerships
    • Expanded Use of Real-World Evidence in Trial Protocols Sustains Growth in Adaptive Trial Frameworks
    • Increasing Emphasis on Patient-Centric Trials Generates Demand for Digital Health Platforms and Remote Monitoring
    • Globalization of Clinical Trials Expands Geographic Footprint and Access to Diverse Patient Populations
    • Limited Availability of Approved Therapies Creates Unmet Need, Propelling Innovation in Pipeline Candidates
    • Growing Focus on Combination Therapies Drives Complexity and Scope of Trial Designs
    • Reimbursement Uncertainty and Market Access Challenges Threaten Commercial Viability Post-Trial
    • Rising Ethical and Regulatory Scrutiny Throws the Spotlight on Transparency in Trial Data and Protocols
    • Emergence of NASH as a Comorbidity in Cardiometabolic Disorders Strengthens Business Case for Integrated Trial Models
    • Advances in Omics Technologies Propel Growth of Biomarker-Driven Clinical Trials
    • Competitive Pressure to Shorten Time-to-Market Drives Demand for Decentralized Trial Models
    • Strategic Collaborations Between Biotech and Academic Institutions Spur Innovation in Early-Stage Trials
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Non-alcoholic Steatohepatitis Clinical Trials Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Phase I by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Phase I by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Phase II by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Phase II by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Phase III by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Phase III by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Phase IV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Phase IV by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Interventional Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Interventional Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Observational Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Observational Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Expanded Access Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Expanded Access Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Non-alcoholic Steatohepatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 18: USA Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 19: USA 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
  • CANADA
    • TABLE 22: Canada Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 23: Canada 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 24: Canada Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Canada 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
  • JAPAN
    • Non-alcoholic Steatohepatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Japan 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 28: Japan Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Japan 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
  • CHINA
    • Non-alcoholic Steatohepatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 30: China Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: China 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 32: China Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: China 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
  • EUROPE
    • Non-alcoholic Steatohepatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 34: Europe Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 35: Europe 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 36: Europe Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Europe 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Europe 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
  • FRANCE
    • Non-alcoholic Steatohepatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 40: France Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: France 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 42: France Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: France 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
  • GERMANY
    • Non-alcoholic Steatohepatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Germany 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 46: Germany Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Germany 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
  • ITALY
    • TABLE 48: Italy Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Italy 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 50: Italy Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Italy 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
  • UNITED KINGDOM
    • Non-alcoholic Steatohepatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 52: UK Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: UK 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 54: UK Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: UK 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Rest of Europe 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 58: Rest of Europe Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Rest of Europe 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Non-alcoholic Steatohepatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 60: Asia-Pacific Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Asia-Pacific 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 64: Rest of World Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Rest of World 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 66: Rest of World Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis Clinical Trials by Study - Interventional Studies, Observational Studies and Expanded Access Studies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Rest of World 6-Year Perspective for Non-alcoholic Steatohepatitis Clinical Trials by Study - Percentage Breakdown of Value Sales for Interventional Studies, Observational Studies and Expanded Access Studies for the Years 2025 & 2030

IV. COMPETITION